Strs Ohio Has $851,000 Stake in Pieris Pharmaceuticals Inc (PIRS)
Strs Ohio raised its holdings in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 1,028.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 112,800 shares of the biotechnology company’s stock after acquiring an additional 102,800 shares during the quarter. Strs Ohio’s holdings in Pieris Pharmaceuticals were worth $851,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in PIRS. Schwab Charles Investment Management Inc. acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at about $292,000. Rhumbline Advisers acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at about $184,000. Bank of New York Mellon Corp acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at about $359,000. Teachers Advisors LLC acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at about $308,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at about $649,000. 50.78% of the stock is owned by institutional investors and hedge funds.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.05% of the stock is currently owned by company insiders.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The company had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $1.52 million. The firm’s revenue was up 400.3% compared to the same quarter last year. equities research analysts forecast that Pieris Pharmaceuticals Inc will post -0.62 EPS for the current fiscal year.
A number of analysts recently issued reports on PIRS shares. ValuEngine cut Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 18th. Finally, William Blair started coverage on Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Pieris Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $10.00.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.